These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32369447)

  • 41. Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma.
    Du EX; Betts KA; Wang T; Kitchen SA; He X; Yin X; Guttenplan SB; Beauchamp K; Delgado A; Rosenblatt L
    Oncol Ther; 2024 Aug; ():. PubMed ID: 39127872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
    Joseph RW; Liu FX; Shillington AC; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Saretsky TL; Pickard AS
    Qual Life Res; 2020 Oct; 29(10):2651-2660. PubMed ID: 32405921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
    Schenk KM; Deutsch JS; Chandra S; Davar D; Eroglu Z; Khushalani NI; Luke JJ; Ott PA; Sosman JA; Aggarwal V; Schollenberger MD; Sharfman WH; Bibee KP; Scott JF; Loss MJ; Wang H; Qi H; Sharon E; Streicher H; Chen HX; Woodward RN; Bagnasco SM; Taube JM; Topalian SL; Brennan DC; Lipson EJ
    J Clin Oncol; 2024 Mar; 42(9):1011-1020. PubMed ID: 38252910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients.
    Reichert C; Baldini C; Mezghani S; Maubec E; Longvert C; Mortier L; Quereux G; Jannic A; Machet L; de Quatrebarbes J; Nardin C; Beneton N; Amini Adle M; Funck-Brentano E; Descamps V; Hachon L; Malissen N; Baroudjian B; Brunet-Possenti F;
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.
    Nomura M; Otsuka A; Yoshimura M; Nonomura Y; Kaku Y; Matsumoto S; Muto M
    Cancer Chemother Pharmacol; 2018 May; 81(5):823-827. PubMed ID: 29502140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
    Pires da Silva I; Lo S; Quek C; Gonzalez M; Carlino MS; Long GV; Menzies AM
    Cancer; 2020 Jan; 126(1):86-97. PubMed ID: 31584722
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Isoda B; Kandori S; Sazuka T; Kojima T; Nitta S; Shiga M; Nagumo Y; Fujimoto A; Arai T; Sato H; Mathis BJ; Wu CL; Jan YH; Ichikawa T; Nishiyama H
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
    J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: A single-center, retrospective cohort study.
    Horisaki K; Yoshikawa S; Omata W; Tsutsumida A; Kiyohara Y
    J Dermatol; 2024 Sep; ():. PubMed ID: 39269143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series.
    Spain L; Walls G; Messiou C; Turajlic S; Gore M; Larkin J
    Cancer Immunol Immunother; 2017 Jan; 66(1):113-117. PubMed ID: 27838762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
    Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma.
    Tachibana H; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Kondo T; Tanabe K; Takagi T
    Clin Genitourin Cancer; 2022 Feb; 20(1):e81-e88. PubMed ID: 34772629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse Events Induced by Nivolumab Plus Ipilimumab
    Kamat S; Patel J; Brown BR; Vyas A
    Cancer Invest; 2022 Oct; 40(9):777-788. PubMed ID: 35916661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.
    Weber JS; Middleton MR; Yates G; Sharpe DJ; Kurt M; Lobo M; Moshyk A; Vanderpuye-Orgle J; Mohr P
    J Clin Oncol; 2024 Oct; ():JCO2400237. PubMed ID: 39378385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.
    Takada R; Fujiwara M; Maki M; Nomura N; Kono S; Fujita A; Masumoto H; Takahashi Y; Hasegawa Y; Tamura K
    J Pharm Health Care Sci; 2024 May; 10(1):26. PubMed ID: 38822426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
    Duerinck J; Lescrauwaet L; Dirven I; Del'haye J; Stevens L; Geeraerts X; Vaeyens F; Geens W; Brock S; Vanbinst AM; Everaert H; Caljon B; Bruneau M; Lebrun L; Salmon I; Kockx M; Tuyaerts S; Neyns B
    Neuro Oncol; 2024 Oct; ():. PubMed ID: 39406392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of nivolumab in advanced melanoma: a drug review.
    Specenier P
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):13-28. PubMed ID: 33225752
    [No Abstract]   [Full Text] [Related]  

  • 58. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis.
    Williamson J; Fadlullah MZH; Kovacsovics-Bankowski M; Gibson B; Swami U; Erickson-Wayman A; Jamison D; Sageser D; Jeter J; Bowles T; Cannon DM; Haaland B; Schroeder JD; Nix D; Atkinson A; Hyngstrom J; McPherson J; Tan AC; Hu-Lieskovan S
    Res Sq; 2023 Jun; ():. PubMed ID: 37398360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.
    Basso U; Paolieri F; Rizzo M; De Giorgi U; Bracarda S; Antonuzzo L; Atzori F; Cartenì G; Procopio G; Fratino L; D'Arcangelo M; Fornarini G; Zucali P; Cusmai A; Santoni M; Pipitone S; Carella C; Panni S; Deppieri FM; Zagonel V; Tortora G
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.